All Outputs (4)

Immunocompromised children and young people are at no increased risk of severe COVID-19 (2021)
Journal Article

Objectives: We aimed to prospectively describe the incidence and clinical spectrum of SARS-CoV-2 infection in immunocompromised paediatric patients in the UK. Methods: From March 2020 to 2021 weekly questionnaires were sent to immunocompromised paedi... Read More about Immunocompromised children and young people are at no increased risk of severe COVID-19.

An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development (2021)
Journal Article

Background & Aims: Development of a prophylactic hepatitis C virus (HCV) vaccine will require accurate and reproducible measurement of neutralizing breadth of vaccine-induced antibodies. Currently available HCV panels may not adequately represent the... Read More about An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development.

Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection (2021)
Journal Article

Understanding the impact of prior infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the response to vaccination is a priority for responding to the coronavirus disease 2019 (COVID-19) pandemic. In particular, it is necess... Read More about Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection.

Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination (2021)
Journal Article

Although SARS-CoV-2 vaccines are very safe, we report 4 cases of the bifacial weakness with paresthesias variant of Guillain–Barré syndrome (GBS) occurring within 3 weeks of vaccination with the Oxford–AstraZeneca SARS-CoV-2 vaccine. This rare neurol... Read More about Guillain–Barré Syndrome Variant Occurring after SARS-CoV-2 Vaccination.